Glenmark gets global rights for diarrhoea drug

Arbiter's ruling will allow Indian pharma major to sell drug in 140 countries

An international arbitrator ruled that India's Pharmaceuticals has the right to sell its HIV-associated diarrhoea drug Crofelemer in 140 countries.

developed Crofelemer with U.S.-based partners Pharmaceuticals and Salix Pharmaceuticals Ltd .

The Indian company sought arbitration in the United States last December after terminated a three-party agreement under which holds the exclusive right to distribute Crofelemer in 140 countries including India.

Salix was to sell the drug in regulated markets such as North America, Japan and Europe.

The International Centre for Dispute Resolution found that breached the agreement by disclosing confidential information about manufacturing Crofelemer to another drugmaker Aptuit Laurus, said in a statement.

Two telephone calls to San Francisco-based seeking comment went unanswered.

"This ruling will allow to further its commitment to working with relief agencies to distribute Crofelemer to affected populations," said Chairman Glenn Saldanha.

Shares in rose 2.3 percent to Rs 415 as of 9:36 a.m. The broader Mumbai market gained 0.26 percent.

 

image
Business Standard
177 22
Business Standard

Glenmark gets global rights for diarrhoea drug

Arbiter's ruling will allow Indian pharma major to sell drug in 140 countries

Reuters 

An international arbitrator ruled that India's Pharmaceuticals has the right to sell its HIV-associated diarrhoea drug Crofelemer in 140 countries.

developed Crofelemer with U.S.-based partners Pharmaceuticals and Salix Pharmaceuticals Ltd .

The Indian company sought arbitration in the United States last December after terminated a three-party agreement under which holds the exclusive right to distribute Crofelemer in 140 countries including India.

Salix was to sell the drug in regulated markets such as North America, Japan and Europe.

The International Centre for Dispute Resolution found that breached the agreement by disclosing confidential information about manufacturing Crofelemer to another drugmaker Aptuit Laurus, said in a statement.

Two telephone calls to San Francisco-based seeking comment went unanswered.

"This ruling will allow to further its commitment to working with relief agencies to distribute Crofelemer to affected populations," said Chairman Glenn Saldanha.

Shares in rose 2.3 percent to Rs 415 as of 9:36 a.m. The broader Mumbai market gained 0.26 percent.

 

RECOMMENDED FOR YOU

Glenmark gets global rights for diarrhoea drug

Arbiter's ruling will allow Indian pharma major to sell drug in 140 countries

An international arbitrator ruled that India's Glenmark Pharmaceuticals has the right to sell its HIV-associated diarrhoea drug Crofelemer in 140 countries.

An international arbitrator ruled that India's Pharmaceuticals has the right to sell its HIV-associated diarrhoea drug Crofelemer in 140 countries.

developed Crofelemer with U.S.-based partners Pharmaceuticals and Salix Pharmaceuticals Ltd .

The Indian company sought arbitration in the United States last December after terminated a three-party agreement under which holds the exclusive right to distribute Crofelemer in 140 countries including India.

Salix was to sell the drug in regulated markets such as North America, Japan and Europe.

The International Centre for Dispute Resolution found that breached the agreement by disclosing confidential information about manufacturing Crofelemer to another drugmaker Aptuit Laurus, said in a statement.

Two telephone calls to San Francisco-based seeking comment went unanswered.

"This ruling will allow to further its commitment to working with relief agencies to distribute Crofelemer to affected populations," said Chairman Glenn Saldanha.

Shares in rose 2.3 percent to Rs 415 as of 9:36 a.m. The broader Mumbai market gained 0.26 percent.

 

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard